The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of dabrafenib and trametinib following progression on BRAF inhibitor monotherapy in metastaticmelanoma: Exploration of clinical and molecular predictors of response.
 
Jennifer Leigh McQuade
No Relationships to Disclose
 
Guo Chen
No Relationships to Disclose
 
David J Panka
No Relationships to Disclose
 
Alexandre Reuben
No Relationships to Disclose
 
Roland L. Bassett
No Relationships to Disclose
 
Aron Joon
No Relationships to Disclose
 
Alexander J. F. Lazar
No Relationships to Disclose
 
Michael T. Tetzlaff
No Relationships to Disclose
 
Lauren Simpson
No Relationships to Disclose
 
Rosalind Mouton
No Relationships to Disclose
 
Sapna Pradyuman Patel
No Relationships to Disclose
 
Isabella Claudia Glitza
No Relationships to Disclose
 
Wen-Jen Hwu
No Relationships to Disclose
 
Rodabe Navroze Amaria
No Relationships to Disclose
 
Adi Diab
No Relationships to Disclose
 
Patrick Hwu
Consulting or Advisory Role - Lion Biotechnologies
Research Funding - Bristol-Myers Squibb; Genentech
 
Jennifer Ann Wargo
No Relationships to Disclose
 
Ryan J. Sullivan
Consulting or Advisory Role - Astex Pharmaceuticals
 
Kevin Kim
Honoraria - Genentech/Roche; GlaxoSmithKline; Novartis
Consulting or Advisory Role - Genentech/Roche; GlaxoSmithKline; Novartis
Research Funding - AstraZeneca (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
 
Michael A. Davies
Consulting or Advisory Role - Genentech/Roche; GlaxoSmithKline; Novartis; Sanofi
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Sanofi (Inst)